Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Dublin, Jan. 15, 2018 -- The "Inhalation Drug Delivery Devices Market" report has been added to ResearchAndMarkets.com's offering.
The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period.
The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million.
Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the inhalation drug delivery devices markets, including MDIs, DPIs, and nebulizers for the treatment of asthma and COPD.
Key Questions Answered
- What are the key drivers and limiters to the inhalation drug delivery devices market?
- Which competitors are leading the market and introducing new technology?
- How are technological advancements impacting market growth?
- What factors are driving epidemiologic growth in the inhalation drug delivery devices market?
Inhalation Market Highlights
- The combined prevalence of asthma and COPD in the countries covered by this report (US, Japan, and five major EU markets of France, Germany, Italy, Spain, and the UK) is 109.3 million.
- The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period.
- Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines.
- The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.
Key Topics Covered:
Executive Summary
- Respiratory disease prevalence
- Inhalation drug delivery devices market
- Selected market drivers and limiters
- Asthma-related devices segment
- COPD-related devices segment
- Market leaders
- Emerging competition
1. Inhalation Drug Delivery Technology
1.1 Technology
- Metered dose inhalers
- Breath-actuated MDIs
- Spacers for use with MDIs
- Dry powder inhalers
- Nebulizers
2. Inhalation Devices for Asthma
2.1 Epidemiology
2.2 Products
- Regulatory guidelines
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co
- SkyePharma/Vectura
- Emerging products
2.3 Market analysis
- Advair and Breo
- Dulera
- Flutiform
- Spiriva
- Symbicort
- Combined market forecast
- US market forecast
- 5EU market forecast
- Japan market forecast
2.4 Bibliography
3. Inhalation Devices for Chronic Obstructive Pulmonary Disease
3.1 Epidemiology
3.2 Products
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co
- Novartis
- Sunovion Pharmaceuticals
- Teva
- Emerging products
3.3 Market analysis
- Duaklir, PT010, Symbicort, and Tudorza
- Spiriva, Stiolto, and Striverdi
- CHF 5993
- Advair, Breo, Anoro, FF/UMEC/VI, and Incruse
- Dulera
- Arcapta, Seebri, Utibron
3.4 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/rkp6gx/global_inhalation?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Delivery
